Clinical Trial Update: Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and potential activity of bevacizumab plus cediranib in patients with metastatic or unresectable solid tumors, lymphoma, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma
• Gliosarcoma
• Lymphoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cediranib (Cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Status: COMPLETED